Clinical Trials Logo

Autistic Disorder clinical trials

View clinical trials related to Autistic Disorder.

Filter by:

NCT ID: NCT00505830 Recruiting - Autism Clinical Trials

Evaluation of the French Version of Screening Questionnaires for Autism and Asperger Syndrome: AQ, EQ and SQ

Start date: July 2007
Phase: N/A
Study type: Observational

Autism is considered as an invading disorder of the development. Asperger Syndrome (AS) is a particular form of autism and is difficult to diagnose. The Autism Spectrum Quotient (AQ) has been developed in order to measure the degree of autistic traits in autistic adolescent with normal intelligence (Baron-Cohen et al. 2001, 2006). AQ comprises 50 questions, with 5 groups of 10 questions assessing imagination, social skills, attention switching, attention to detail and communication skills. Each of these items scores 1 point if the respondent records abnormal or autistic like behaviour. The minimum score on the AQ is 0 and the maximum 50. The principal objective of this study is to evaluate the accuracy of the French version of Autism Spectrum Quotient questionnaire. Secondary objectives are to: Evaluate if EQ and SQ can distinguish adolescents without psychiatric syndromes from those with classical autism or AS. Evaluate if AQ, EQ and SQ can distinguish adolescents with psychiatric disorders from autistic adolescents. Define the threshold of positivity for the 3 questionnaires.

NCT ID: NCT00503191 Completed - Autism Clinical Trials

NeuroModulation Technique Treatment of Autism

NMT
Start date: July 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether NeuroModulation Technique (NMT) is effective in reducing maladaptive behaviors and increasing adaptive behaviors in children diagnosed with autism. Hypothesis: Children in the Experimental group will show significant improvement over the Wait-List control group as measured by the Pervasive Developmental Disorder Behavioral Inventory (PDDBI), the Aberrant Behavior Checklist, Community Version (ABC-C), and the Autism Treatment Evaluation Checklist (ATEC). Children in the Wait-List control group will show significant improvement over their baseline measures after receiving NMT treatment.

NCT ID: NCT00498173 Completed - Autism Clinical Trials

Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism

Start date: July 2007
Phase: Phase 3
Study type: Interventional

This study will evaluate the effectiveness of atomoxetine in treating children with attention deficit hyperactivity disorder symptoms associated with autistic disorder, Asperger's syndrome, and pervasive developmental disorder, not otherwise specified.

NCT ID: NCT00494754 Completed - Autism Clinical Trials

Clinical and Genetic Study of Autism Spectrum Disorder

Start date: May 2007
Phase:
Study type: Observational

The purpose of this study is to prepare instruments for Autism Spectrum Disorder (ASD), to collect clinical, neuropsychological, and genetic data of ASD probands and their family, and to identify the genetic variants close to etiological genes of ASD in a Taiwanese sample

NCT ID: NCT00490802 Completed - Autism Clinical Trials

Intranasal Oxytocin in the Treatment of Autism

Start date: June 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to learn whether or not the drug called oxytocin is helpful in improving mood and social functioning in adults with autism.

NCT ID: NCT00468130 Completed - Autism Clinical Trials

Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children

Abilify
Start date: May 2006
Phase: N/A
Study type: Interventional

Hypothesis: (1) Aripiprazole treatment will be superior to placebo in reducing aggression and irritability in autistic individuals as shown by reductions in the Aberrant Behavior Checklist-irritability subscale. (2) Aripiprazole treatment will be superior to placebo in the acute treatment of global autism severity. The purpose of this study is to examine the possible benefit of the medication Aripiprazole in autistic individuals.

NCT ID: NCT00467818 Completed - Autism Clinical Trials

Omega 3 Fatty Acids in the Treatment of Children With Autism Spectrum Disorders

Start date: January 2007
Phase: N/A
Study type: Interventional

Published studies on omega 3 fatty acids in the treatment of bipolar disorder and schizophrenia have shown reductions in time to recurrence, a decrease in the positive and negative symptoms of schizophrenia, and improvements in Clinical Global Impression Scale, Young Mania Rating Scale, and HAM-D scores. The following are the hypotheses: - Omega 3 fatty acids will be superior to placebo in the acute treatment of global autism. - Omega 3 fatty acids will be superior to placebo in improving aggression and irritability associated with autism. - Omega 3 fatty acids will be superior to placebo in improving functional ability.

NCT ID: NCT00467753 Completed - Autism Clinical Trials

Oxcarbazepine Versus Placebo in Childhood Autism

Start date: April 2006
Phase: N/A
Study type: Interventional

The proposed study is designed to assess the effectiveness of treatment with Oxcarbazepine vs. placebo in childhood/adolescent autism. This is a twelve-week study involving twenty subjects between the ages of five and seventeen with a diagnosis of autism.

NCT ID: NCT00464477 Completed - Autistic Disorder Clinical Trials

Advanced Grandparental Age as a Risk Factor for Autism

Start date: June 2007
Phase: N/A
Study type: Observational

The Division of Medical Genetics at the University of Mississippi Medical Center is recruiting parents of children with a pervasive developmental disorder (including autism, autistic spectrum disorder, PDD-NOS, Asperger syndrome, childhood disintegrative disorder, and Rett syndrome) to participate in a study to help determine potential causes of the increasing prevalence of these disorders. The study is being conducted using an anonymous on-line survey available to parents through a secure link. The study consists of approximately 90 questions about the affected child, siblings, parents, and grandparents, which will take roughly 10-15 minutes to complete. Several families will also be invited to participate in a phone interview. Both the survey and the phone interview are conducted using a self-designated code to protect anonymity and patient privacy. No identifying information such as name, date of birth, address, or phone number will be asked. Only questions regarding the year of birth of family members will be asked.

NCT ID: NCT00463164 Not yet recruiting - Autism Clinical Trials

Functional MRI of Cognitive Control in Autism

Start date: December 2007
Phase: N/A
Study type: Observational

This study aims to investigate the role of fronto-striatal circuits and cognitive control in the perseverative and inflexible behavior that is a defining feature of autism. We hypothesize that deficits in the development of fronto-striatal circuitry may underlie cognitive inflexibility in autism. Specifically, we hypothesize that repetitive, inflexible behavior arises as (1) fronto-striatal systems are capable of learning patterns present in the environment (as in implicit learning paradigms), but are unable to adapt behavior to changing circumstances, related to either (2) decreased ability of basal ganglia to detect violations of expectancy, (3) decreased ability of prefrontal cortex to respond to detected violations, or (4) decreased connectivity of the circuits. We are conducting three functional Magnetic Resonance Imaging (fMRI) studies to address these hypotheses.